S0441

SB-366791

≥98% (HPLC), powder

• Synonim(y): N-(3-Methoxyphenyl)-4-chlorocinnamide
• Wzór empiryczny (zapis Hilla): C₁₆H₁₄NO₂Cl
• Numer CAS: 472981-92-3
• Masa cząsteczkowa: 287.74
• NACRES: NA.77
• PubChem Substance ID: 24278690
• UNSPSC Code: 12352200
• MDL number: MFCD01033818
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 200
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 5 mg/mL, clear
• originator: GlaxoSmithKline
• SMILES string: COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1
• InChI: 1S/C16H14ClNO2/c1-20-15-4-2-3-14(11-15)18-16(19)10-7-12-5-8-13(17)9-6-12/h2-11H,1H3,(H,18,19)/b10-7+
• InChI key: RYAMDQKWNKKFHD-JXMROGBWSA-N
• Gene Information: human ... TRPV1(7442)

Opis

Application

SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:

• to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
• to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
• to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)[1]

Biochem/physiol Actions

SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.

Vanilloid receptor-1 (TRPV1) antagonist.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)